Dianthus Therapeutics, Inc.
NasdaqCM DNTH
Dianthus Therapeutics, Inc. Market Capitalization on January 14, 2025: USD 588.24 M
Dianthus Therapeutics, Inc. Market Capitalization is USD 588.24 M on January 14, 2025, a 116.43% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
-
Dianthus Therapeutics, Inc. 52-week high Market Capitalization is USD 884.95 M on November 07, 2024, which is 50.44% above the current Market Capitalization.
-
Dianthus Therapeutics, Inc. 52-week low Market Capitalization is USD 255.15 M on January 18, 2024, which is -56.62% below the current Market Capitalization.
-
Dianthus Therapeutics, Inc. average Market Capitalization for the last 52 weeks is USD 713.08 M.
Key data
| Date | Market Capitalization | Share Price | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) |
|---|
Market news
Loading...
NasdaqCM: DNTH
| CEO | Mr. Marino Garcia M.B.A. |
| IPO Date | June 21, 2018 |
| Location | United States |
| Headquarters | 7 Times Square |
| Employees | 53 |
| Sector | Health Care |
| Industries | |
Description
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email